RMIT University, located in Melbourn, Australia, has announced that it will display the Respite surface acoustic wave nebulizer at TechInnovation 2015. According to RMIT, the device can deliver drug at rates of 3 ml/min, with no meshes or nozzles that could clog. The Respite nebulizer has the ability to deliver DNA, proteins, and peptides, and RMIT researchers envision its use for delivering insulin, vaccines, and lung cancer therapies.
MicroNanophysics Research Laboratory Director Leslie Yeo, a Professor of Chemical Engineering at the university, said, “The five-year survival rate for lung cancer remains around 15 per cent despite the significant therapeutic advances achieved in recent years and currently, there are no personalized delivery devices for inhaled cancer drugs to improve these clinical outcomes. Our nebulizer addresses this gap as a low-cost and convenient yet efficient method of delivering oncolytics directly to the lungs, potentially revolutionizing the treatment of lung cancer.”
Read the RMIT press release.
